UTHR

$538.34+4.04 (+0.76%)

Market OpenAs of Mar 17, 7:00 PM UTC

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$538.34
Potential Upside
13.5%
Whystock Fair Value$610.89
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$23.59B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.34
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
19.71%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
5.83

Recent News

Motley Fool
Mar 16, 2026

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 16, 2026

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 14, 2026

Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential

United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary fibrosis, published in the New England Journal of Medicine. The study showed meaningful preservation of lung function and a reduction in clinical worsening for IPF patients treated with Tyvaso. If approved by the FDA, Tyvaso could become the first and only inhaled anti fibrotic treatment for IPF, expanding United Therapeutics' potential addressable market. United...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 13, 2026

United Therapeutics Stock Surges 32% in 6 Months: Here's Why

UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 10, 2026

United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?

United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.